Comparing the effectiveness of Empagliflozin with Metformin in controlling Diabetes Mellitus in patients with post-organ transplant diabetes

Comparing the effectiveness ofEmpagliflozin with Metformin in controlling Diabetes Mellitus in patients with post-organ transplant diabetes

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230315057726N1

Enrollment

Registered

2023-08-26

Start date

2023-08-01

Completion date

Unknown

Last updated

2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post Transplant Diabetes Mellitus. Other specified diabetes mellitus

Interventions

Intervention 1: Intervention group A: Empagliflozin 10mg(?Iran, Tehran, Abidi Pharmaceutical Company) for 3 months. Intervention 2: Intervention groupB: Metformin 500 mg(?Iran, Alborz, Actoverco Pharm

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: At least 6 months have passed since the patient's transplant No previous history of diabetes and use of any blood sugar-lowering medication Diagnosing diabetes according to the criteria of the American Diabetes Association HbA1c6.5%

Exclusion criteria

Exclusion criteria: Rejection of the transplanted organ in the patient Transplanted organ failure Pregnancy Age less than 18 years Any contraindication related to empagliflozin (allergy to the drug or its components, dialysis, diabetic ketoacidosis, hospitalization) The patient's unwillingness to participate in the study BMI above 40 Severe liver failure (enzymes more than 3 times the normal limit) or renal failure (creatinine more than 2), creatinine clearance below 60 Any contraindication related to Metformin (allergy to the drug or its components, dialysis, diabetic ketoacidosis, hospitalization)

Design outcomes

Primary

Measure	Time frame
HbA1c. Timepoint: To compare the effectiveness of two drugs, empagliflozin and metformin, HbA1C of patients with Post Transplant Diabetes Mellitus(PTDM) is measured at the beginning of the study and 90 days after taking the drug. Method of measurement: Blood Sample.	—

Secondary

Measure	Time frame
FBS (fasting blood sugar). Timepoint: To compare the effectiveness of two drugs, empagliflozin and metformin, FBS of patients with Post Transplant Diabetes Mellitus(PTDM) is measured at the beginning of the study and 90 days after taking the drug. Method of measurement: Blood Sample.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAmirhossein niknejad

Islamic Azad University

amirhosseinniknejad@gmail.com+98 21 2202 3410

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026